INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
July 10 2023 - 4:00PM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, announces important findings from
data presented at The 16th European Meeting on Glial Cells in
Health and Disease. The conference runs July 8-12 in
Berlin, Germany.
Myelin is a specialized lipid produced by oligodendrocytes that
forms the myelin sheath of axons. Axons are the projections
that allow neurons to communicate with each other and with other
tissues such as muscle, skin, retina, nose and the ear for sight,
smell and hearing respectively. An intact and healthy myelin
sheath is necessary for axons to work properly. Any damage to
the myelin sheath compromises axon function preventing nerve cells
from communicating and can result in nerve cell death.
Although the pathology of demyelination is easy to see, the biology
of demyelination and remyelination is poorly understood. Drug
therapy to prevent demyelination are available, but there are no
therapies that promote remyelination. Therapies that promote
remyelination will be needed to effectively treat many
neurodegenerative diseases.
“Demyelination is an important part of the pathology of many
neurodegenerative diseases including multiple sclerosis (MS) and
Alzheimer’s disease (AD). In the past, microglia cells were
thought to drive demyelination,” said Prof. Lesley Probert Ph.D.
from the Hellenic Pasteur Institute in Athens, Greece. “This
work shows that astrocytes, the most abundant cell in the
brain after neurons, like microglia, are intimately involved in
driving the neuroinflammation component in demyelinating diseases,
and that blocking soluble TNF with XPro™ promotes
remyelination.” Prof. Probert’s team has previously shown
that XPro™ promotes remyelination in the cuprizone model – a
standard model for studying myelin biology in the brain. Work
continues to determine how XPro™ affects microglia and astrocyte
responses to promote disease resolution and repair. The data
presented today demonstrate new findings. First, astrocytes
are rapidly activated in response to demyelination. Second,
preventing soluble TNF and TNFR1 function in mice using microglia-
or astrocyte-specific TNFR1 knockout mice mirrors the effects
of XPro™ in increasing beneficial glial responses that results
in better remyelination. The third surprise is that traditional
biomarkers of astroglial and microglial activation, GFAP and Iba1
respectively, are increased in these myelin-promoting glial
cells.
"Until recently, the of role in demyelination and remyelination
has been poorly understood. This work shows that microglia and
astroglia must express biomarkers of activation to promote
remyelination,” said Dr. CJ Barnum VP of CNS Drug Development at
INmune Bio. "This finding is contrary to current dogma that
suggests decreased glial activation is required to promote
remyelination. This finding supports our belief that
immunosuppressive therapies that turn off the glial cells will not
help repair and regeneration of the brain in neurologic
diseases." These data will be expanded in a detailed
publication in the future.
List of Presentations:
Distinct astrocyte activation profiles associated with
demyelination in the cuprizone model of multiple sclerosis.
Therapeutic modulation of solTNF-TNFR1 signaling selectively
in microglia promotes remyelination in the cortical grey
matter.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused
on developing treatments that target the innate immune system to
fight disease. INmune Bio has two product platforms that are both
in clinical trials. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF,
a key driver of innate immune dysfunction and mechanistic target of
many diseases. DN-TNF is in clinical trials to determine if it can
treat cancer (INB03™), early Alzheimer’s disease, and treatment
resistant depression (XPro™). The Natural Killer Cell Priming
Platform includes INKmune™ aimed at priming the patient’s NK cells
to eliminate minimal residual disease in patients with cancer.
INmune Bio’s product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more,
please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595™, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720 info@inmunenbio.com
Investor Contact: Jason Nelson Core IR (516)
842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024